Blockchain Registration Transaction Record

SureNano Science Enters GLP-1 Race with Novel Triple Agonist

SureNano Science (SURNF) is developing GEP-44, a triple agonist peptide for obesity, targeting GLP-1 and PYY receptors. Learn about its potential advantages over first-generation GLP-1 therapies.

This news matters because obesity and metabolic diseases affect hundreds of millions globally, and current GLP-1 therapies have limitations in tolerability and delivery. SureNano's GEP-44, with its triple agonist mechanism and potential for non-injectable delivery, could offer a more patient-friendly and effective treatment option. If successful, it may disrupt the booming weight-loss drug market, providing alternatives that improve compliance and outcomes. For investors, SureNano represents a high-risk, high-reward microcap play in a sector dominated by pharma giants.